SCHEMBL249052

SCHEMBL249052

CCCCCCCCCCCC(=O)N1CCCC1

nearest known ligand 0.96

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.96
MEN1 O00255 2/20 0.92
KMT2A Q03164 2/20 0.92
TDP1 Q9NUW8 1/20 0.92
ATM Q13315 1/20 0.68
GNAI3 P08754 9/20 0.68
GNAI1 P63096 9/20 0.68
GNAO1 P09471 8/20 0.64
POLB P06746 1/20 0.54
MAPT P10636 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27508518 1.00 L3MBTL1 (0.96) L3MBTL1MEN1KMT2ATDP1ATM
SCHEMBL10494122 1.00 L3MBTL1 (0.96) L3MBTL1MEN1KMT2ATDP1ATM
SCHEMBL28152342 1.00 L3MBTL1 (0.96) L3MBTL1MEN1KMT2ATDP1ATM
SCHEMBL10534175 1.00 L3MBTL1 (0.96) L3MBTL1MEN1KMT2ATDP1ATM
N-(Decanoyl)Pyrrolidine SCHEMBL10755236 1.00 L3MBTL1 (0.96) L3MBTL1MEN1KMT2ATDP1ATM
SCHEMBL151361 1.00 L3MBTL1 (0.96) L3MBTL1MEN1KMT2ATDP1ATM
N-(Decanoyl)Pyrrolidine SCHEMBL692598 1.00 L3MBTL1 (0.96) L3MBTL1MEN1KMT2ATDP1ATM
SCHEMBL10534171 1.00 L3MBTL1 (0.96) L3MBTL1MEN1KMT2ATDP1ATM
SCHEMBL10290341 1.00 L3MBTL1 (0.96) L3MBTL1MEN1KMT2ATDP1ATM
SCHEMBL28149836 1.00 L3MBTL1 (0.96) L3MBTL1MEN1KMT2ATDP1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250195409-A1 METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES Ananda Scientific, Inc. (US) 2025-06-19 US disclosed
EP-2945604-B1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND AN OILY PHASE COMPRISING AT LEAST ONE SPECIFIC AMIDE COMPOUND OREAL (FR) 2019-04-10 EP disclosed
US-9993405-B2 Cosmetic or dermatological composition comprising a merocyanine and an oily phase comprising at least one specific amide compound L'OREAL (FR) 2018-06-12 US disclosed
US-9993405-B2 Cosmetic or dermatological composition comprising a merocyanine and an oily phase comprising at least one specific amide compound L'OREAL (FR) 2018-06-12 US disclosed
US-20150359718-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND AN OILY PHASE COMPRISING AT LEAST ONE SPECIFIC AMIDE COMPOUND L'OREAL (FR) 2015-12-17 US disclosed
US-20150359718-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND AN OILY PHASE COMPRISING AT LEAST ONE SPECIFIC AMIDE COMPOUND L'OREAL (FR) 2015-12-17 US disclosed
EP-2588506-B1 SELF LIMITING CATALYST COMPOSITION FOR ETHYLENE POLYMERIZATION DOW GLOBAL TECHNOLOGIES LLC (US) 2015-10-07 EP disclosed
US-20150250882-A1 Fatty Acid Acylated Amino Acids for Growth Hormone Delivery NOVO NORDISK HEALTHCARE AG (CH) 2015-09-10 US disclosed
US-8993692-B2 Self limiting catalyst composition for ethylene polymerization DOW GLOBAL TECHNOLOGIES LLC (US) 2015-03-31 US disclosed
WO-2014111570-A2 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND AN OILY PHASE COMPRISING AT LEAST ONE SPECIFIC AMIDE COMPOUND L'OREAL (FR) 2014-07-24 WO disclosed
US-20130131289-A1 SELF LIMITING CATALYST COMPOSITION FOR ETHYLENE POLYMERIZATION DOW GLOBAL TECHNOLOGIES LLC (US) 2013-05-23 US disclosed
EP-2588506-A1 SELF LIMITING CATALYST COMPOSITION FOR ETHYLENE POLYMERIZATION Dow Global Technologies LLC (US) 2013-05-08 EP disclosed
WO-2012003219-A1 SELF LIMITING CATALYST COMPOSITION FOR ETHYLENE POLYMERIZATION DOW GLOBAL TECHNOLOGIES LLC (US) 2012-01-05 WO disclosed
WO-2009077844-A2 INHIBITORS OF BIOFILM FORMATION OF GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA QUONOVA LLC (US) 2009-06-25 WO disclosed
US-4837026-A Transdermal and systemic preparation and method THERAPEUTIC PATCH RESEARCH N.V. 1989-06-06 US disclosed
US-4716060-A ACYCLIC OR HETEROCYCLIC TERTIARY AMIDE RAJADHYAKSHA VITHAL J (US) 1987-12-29 US disclosed
EP-0240554-A1 TRANSDERMAL AND SYSTEMIC PREPARATION AND METHOD RAJADHYAKSHA, Vithal J. (US) 1987-10-14 EP disclosed
WO-1987001935-A1 TRANSDERMAL AND SYSTEMIC PREPARATION AND METHOD RAJADHYAKSHA VITHAL J 1987-04-09 WO disclosed
US-4171975-A MAGENTA COUPLER AND AN AMIDE KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) 1979-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150359718-A1 COSMETIC OR DERMATOLOGICAL COMPOSITION COMPRISING A MEROCYANINE AND AN OILY PHASE COMPRISING AT LEAST ONE SPECIFIC AMIDE COMPOUND KRT18, CUTA, CRYZ L3MBTL1 4739/4885MEN1 1077/4885KMT2A 804/4885
US-20250195409-A1 METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES CNR2, CNR1, FAAH L3MBTL1 4862/4885MEN1 4840/4885KMT2A 2718/4885
US-20150250882-A1 Fatty Acid Acylated Amino Acids for Growth Hormone Delivery GHRHR, GHSR, GHITM L3MBTL1 4415/4885MEN1 2160/4885KMT2A 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.